Tianjin Medical Univ. PARP-1 compound 4

Tianjin Medical Univ. PARP-1 compound 4: sourced facts only. name: "Representative compound 4 displayed the most potent antitumor effect by synergizing theophylline-induced PARP-1 inhibition with platinum-induced DNA damage to fully exert synthetic lethality in BRCA1-deficient cells with homologous recombination repair deficiencies." [PMID:40632681]; target: "Representative compound 4 displayed the most potent antitumor effect by synergizing theophylline-induced PARP-1 inhibition with platinum-induced DNA damage to fully exert synthetic lethality in BRCA1-deficient cells with homologous recombination repair deficiencies." [PMID:40632681]; developer: "Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China." [PMID:40632681]; stage: "In SKOV3-BRCA1-KD xenograft models, 4 exhibited 71.70% tumor growth inhibition, surpassing cisplatin (50.48%) and olaparib (47.63%), with mitigated nephrotoxicity." [PMID:40632681]